Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK plc has repurchased 560,000 of its ordinary shares on 20 March 2026 via BNP Paribas under its existing share buyback programme, paying a volume‑weighted average price of 1,953.58p and retaining the shares in treasury. The transaction, which brings total buybacks since 17 February 2026 to 13,331,521 shares, increases treasury holdings to 253,222,615 shares, leaves 4,062,953,663 shares in issue with voting rights, and results in 6.23% of voting rights now attributable to treasury stock, implications that investors may factor into ownership and transparency calculations.
The company’s active buyback programme and rising treasury position underline ongoing capital management efforts that can support earnings per share and signal confidence in its valuation, though they also modestly reduce the free float. The updated voting rights figure provides a new reference point for shareholders monitoring disclosure thresholds and regulatory reporting obligations under the UK’s transparency rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2136.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing, manufacturing and marketing vaccines, prescription medicines and consumer healthcare products. The group targets major therapeutic areas including infectious diseases, respiratory conditions and immunology, with a broad presence across Europe, the U.S. and other international markets.
Average Trading Volume: 8,894,945
Technical Sentiment Signal: Buy
Current Market Cap: £78.03B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.